Kengreal FDA Approved Drugs
KENGREAL [CangrelorC17H25Cl2F3N5O12P3S2]
RX
- 50mg/vial (iv (infusion) powder)
Chiesi Usa IncJun 22, 2015
- Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci.
- P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.